Key result
Haploidentical HCT normalizes TRV and improves cardiac morphology by one year in sickle cell disease.
Why the study?
The effects of haploidentical hematopoietic cell transplantation on cardiac morphology and function in adults with sickle cell disease are not fully understood.
Does haploidentical hematopoietic cell transplantation improve cardiac morphology in adults with sickle cell disease?
Cohort
Does haploidentical hematopoietic cell transplantation improve cardiac morphology in adults with sickle cell disease?
p-value: p=.001
Haploidentical HCT in adults with sickle cell disease improves cardiac morphology and normalizes TRV at 1 year, suggesting potential cardiovascular benefits beyond anemia resolution.
May support cardiac benefits of haploidentical HCT in SCD adults; hypothesis-generating and should not yet change practice.
; P = .001). Furthermore, mean TRV normalized by 1 year, suggesting that HCT may offer a survival benefit. Fewer patients had pathologically prolonged native myocardial T1 times, an indirect marker of myocardial fibrosis at 1 year; these data showed a trend toward significance. In this small sample, CMR was very sensitive in detecting cardiac mass and volume changes after HCT and provided complementary information to echocardiography. Notably, post-HCT improvement in cardiac parameters can be attributed only in part to the resolution of anemia; further studies are needed to determine the roles of myocardial fibrosis reversal, improved blood flow, and survival impact after HCT for SCD.
No takes yet. Share an insight, caveat, or question.
Limerick et al. (2023) conducted a cohort in Sickle Cell Disease. Haploidentical Hematopoietic Cell Transplantation was evaluated (p=.001). Haploidentical hematopoietic cell transplantation in adults with sickle cell disease led to normalized mean TRV by 1 year (P = .001) and improvements in cardiac morphology.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: